--News Direct--

Palatin Technologies* has unveiled compelling topline results from its Phase 2 study showing that patients receiving its obesity drug bremelanotide in combination with tirzepatide achieved a 4.4% weight reduction compared to just 1.6% for placebo—a highly statistically significant difference (p<0.0001). The eight-week trial demonstrated that combining these two mechanisms creates a synergistic effect, with 40% of patients in the combination group achieving at least 5% weight loss compared to 27% with tirzepatide alone.

The economic potential of anti-obesity drugs is enormous, with the market expected to reach US$100 billion by 2030. As obesity rates continue to climb globally, with the number of obese individuals worldwide projected to increase from 980 million to nearly 2 billion from 2022 to 2035, innovative treatment approaches like Palatin's are positioning themselves in this rapidly expanding market.

Perhaps most intriguing for the obesity treatment landscape, Palatin's data revealed that its drug effectively halted the rapid weight regain typically seen after stopping GLP-1/GIP therapy. This addresses one of the most significant challenges facing current obesity treatments, where patients often regain substantial weight after discontinuation.

The economic potential of anti-obesity drugs is enormous, with the market expected to reach US$100 billion by 2030. As obesity rates continue to climb globally, with the number of obese individuals worldwide projected to increase from 980 million to nearly 2 billion from 2022 to 2035, innovative treatment approaches like Palatin's are positioning themselves in this rapidly expanding market.

Palatin is advancing development of next-generation long-acting injectable and oral versions of its obesity compounds, with investigational new drug applications planned for late 2025 and clinical data expected in early 2026. The company is one of just two developing therapies targeting this specific biological pathway for obesity.

This announcement follows recent positive news from Palatin's ulcerative colitis program and FDA orphan drug designation for its oral obesity compound for rare genetic obesity disorders, demonstrating the company's momentum across multiple therapeutic areas with significant unmet needs.

Subscribe For More Alerts:

https://newsletter.page/wallstreetalerts

Recent Palatin Technologies News Highlights:

• Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

• Completion of Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

• Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

• Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

*DISCLAIMER: This alert is published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This alert contains and is a form of paid promotional content for to Palatin Technologies and was produced as part of their paid subscription to Wall Street Wire’s distribution and promotional content services. This alert has not been reviewed or approved by Palatin Technologies prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms

Contact Details

Wall Street Wire

Market Aerts Desk

media.globalmarkets@gmail.com

View source version on newsdirect.com: https://newsdirect.com/news/market-alert-palatins-disruptive-obesity-drug-combination-shows-groundbreaking-weight-loss-results-in-phase-2-topline-data-nyse-ptn-123973562